Shots:

• The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (atezolizumab- 1200mg) + Avastin (bevacizumab- 15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg- bid) on days 1-21 of each 21-day cycle in 501 patients in a ratio (2:1) with unresectable HCC- prior not treated with systemic therapies
• Result: reduction in the risk of OS (42%); reduction in the risk of disease worsening or death- PFS (41%); showed improvement in both OS and PFS; Grade 3–4 AEs (57% vs 55%)- published in the NEJM
• The approval follows an EMA’s CHMP positive opinion received in Sept’2020. The dual regimen also recently included as a class I- A recommendation by the ESMO for unresectable HCC- as well as by many clinical practice guidelines globally

  Ref: Roche | Image: Roche